Source: NEJM
Area: News
The results of two phase 3 trials investigating the use of intravitreal ocriplasmin in vitreomacular adhesion have been published in the New England Journal of Medicine (NEJM). In vitreomacular adhesion, the vitreous gel adheres in an abnormally strong manner to the retina resulting in pathologic traction, retinal tears and macular hole. Vitreolysis involving an enzyme that is active against the molecular substances responsible for vitreomacular adhesion has been postulated as a potential non-surgical approach to treating this condition. Ocriplasmin is a recombinant protein with retained protease activity against fibronectin and laminin, components of the vitreoretinal interface.
Both studies (study 006 and study 007) were designed as multicentre, randomised, double-blind trials that assessed the efficacy and safety of a single intravitreal injection of ocriplasmin. Patients with symptomatic vitreomacular adhesion were randomised to treatment with ocriplasmin (125 mcg ...
Uncategorized